Daré Bioscience, Inc. (DARE) - 10-K Summary
Business Context and Reporting Period
Company: Daré Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Daré is a biopharmaceutical company focused on women's health, developing products in contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company operates as a single segment. Its only FDA-approved product, XACIATO (clindamycin phosphate vaginal gel), is commercialized by Organon. Daré's strategy involves advancing its pipeline through clinical development and utilizing Section 503B compounding for certain formulations, such as Sildenafil Cream, to generate non-dilutive revenue.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $9,784 | $2,807,885 |
| Net Loss | $(4,053,599) | $(30,161,391) |
| Operating Expenses | $23,461,269 | $33,747,765 |
| Research & Development (R&D) | $14,205,208 | $21,538,074 |
| General & Administrative (G&A) | $9,156,061 | $12,109,691 |
| Cash and Cash Equivalents (Dec 31, 2024) | $15,698,174 | $10,476,056 |
| Working Capital | Deficit of ~$3.2 million | Deficit of ~$2.9 million |
| Accumulated Deficit | $(175.3 million) | $(171.2 million) |
Note: The 2024 Net Loss was significantly reduced by a one-time gain of $20.4 million (net of transaction costs) from the sale of royalty and milestone rights to XOMA.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped from $2.8 million in 2023 to less than $10,000 in 2024. This is primarily due to the April 2024 sale of future royalty and milestone rights for XACIATO to XOMA. Consequently, future royalties from XACIATO sales are now payable to XOMA (and UiE) rather than recognized as revenue by Daré.
- Significant One-Time Gain: The company recognized $20.4 million in "Other income" from the sale of royalty rights to XOMA, which offset a large portion of operating losses.
- Expense Reduction: Total operating expenses decreased by approximately $10.3 million (30%) year-over-year. R&D expenses fell by $7.3 million, largely due to the completion of the Phase 2b RESPOND study for Sildenafil Cream, partially offset by increased costs for the Ovaprene Phase 3 trial.
- Grant Funding: The company recognized approximately $8.8 million in contra-R&D expenses (grant funding) in 2024, compared to $9.3 million in 2023.
Guidance, Outlook, and Risks
Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, the company had a working capital deficit of approximately $3.2 million and cash of $15.7 million. Management states it will need additional capital to fund operations into the third quarter of 2025.
Strategic Outlook:
- Ovaprene: The pivotal Phase 3 clinical study is ongoing but faces significant uncertainty. Recruitment at NICHD Contraceptive Clinical Trials Network (CCTN) sites was paused in Q1 2025 due to federal government actions impacting NICHD's ability to manage contracts. The company is recruiting at five new sites funded by a Gates Foundation grant.
- Sildenafil Cream: The company plans to launch this product via Section 503B compounding in Q4 2025 to generate revenue while continuing to pursue FDA approval for the treatment of Female Sexual Arousal Disorder (FSAD).
- Capital Raising: The company has an equity line of credit with Lincoln Park Capital Fund for up to $15.0 million and an ATM facility with Stifel. It is actively seeking additional capital through equity, debt, or strategic collaborations.
Key Risks:
- Nasdaq Delisting: The company failed to meet the Nasdaq Minimum Market Value of Listed Securities rule ($35 million) by the February 10, 2025 deadline. A hearing was held on March 25, 2025, and the company is awaiting a decision on whether an extension period will be granted to regain compliance.
- Government Funding Uncertainty: Changes in U.S. federal policy and funding under the new presidential administration have negatively impacted the Ovaprene Phase 3 study and create uncertainty for future grants supporting DARE-HPV and other programs.
- Liquidity: Failure to raise additional capital could force the company to delay, scale back, or terminate product development programs.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of ongoing capital raising efforts (equity line, ATM, private placements).
- Nasdaq Compliance: Monitor the outcome of the Nasdaq Hearing Panel decision regarding the delisting notice and any granted extension periods.
- Ovaprene Trial Status: Confirm the impact of the NICHD contract pause on enrollment rates and the timeline for the Phase 3 study completion.
- 503B Launch: Track progress on establishing partnerships with outsourcing facilities for the Q4 2025 launch of Sildenafil Cream.
- XOMA Agreement: Understand the threshold ($88 million) XOMA must reach before Daré begins sharing in future XACIATO royalties.